Overview
The aim of the study is to compare the 12-month clinical outcomes of patients with patellofemoral osteoarthritis undergoing infiltrative treatment with fresh PRP and HA
Description
166 patients affected by patellofemoral osteoarthritis will be included in a double-blinded RCT. In this study one group of patients will be treated with 1 intra-articular injection of PRP (treatment arm) and one group will be treated with 1 intra-articular injection of HA (control arm). Patients will be followed-up with clinical evaluation at baseline and at 2.6.12 and 24 months. Questionnaires will be administered for clinical evaluations during the follow-up visits.
Eligibility
Inclusion Criteria:
- Age between 30 and 65;
- Signs and symptoms of isolated patellofemoral osteoarthritis present in one or both knees;
- Radiographic signs of isolated patellofemoral osteoarthritis (according to Iwano et al stage 1-3 classification) or chondropathy (assessed on MRI) with K-L grade of the other compartments ≤ 2. [PMID: 2302884 - PMID: 27979409] ;
- Hemoglobin > 11 g/dl; Platelet count > 150,000 plt/mm3 (Recently performed CBC exam);
- No clinically significant electrocardiographic alterations (Recently performed ECG).
- Ability and consent of patients to actively participate in clinical follow-up;
- Signature of informed consent.
Exclusion Criteria:
- Patients unable to express consent;
- Patients who have undergone intra-articular infiltration of another substance within the previous 6 months;
- Patients undergoing knee surgery within the previous 12 months;
- Patients with malignant neoplasms;
- Patients with rheumatic diseases;
- Patients with diabetes;
- Patients with hematologic diseases (coagulopathies);
- Patients on anticoagulant-antiaggregant therapy;
- Patients with thyroid metabolic disorders;
- Patients abusing alcoholic beverages, drugs or medications;
- Body Mass Index > 35;
- Patients who have taken NSAIDs in the 3 days prior to blood draw;
- Patients with cardiovascular disease for which a 60 mL blood draw would be contraindicated;
- Patients with a recently performed blood test with Hb< 11 g/dl and Platelets < 150,000 plt/mm3.
- Previous treatment of patellar dislocation
- Iwano score of grade 4.